Brief: Vyne Therapeutics Reports Positive Results From Preclinical Models For Oral BD2-Selective BET Inhibitor VYN202

YARROW BIOSCIENCE

30/10/2023 11:23

Oct 30 (Reuters) - Vyne Therapeutics Inc  VYNE.O :
    * VYNE THERAPEUTICS REPORTS POSITIVE RESULTS FROM
PRECLINICAL
MODELS FOR ORAL BD2-SELECTIVE BET INHIBITOR VYN202
    * VYNE THERAPEUTICS INC: CO EXPECTS TO INITIATE A PHASE 1A
SAD/MAD
CLINICAL TRIAL IN Q1 2024
    * VYNE THERAPEUTICS INC - VYNE EXPECTS TO SUBMIT ITS IND FOR
VYN202 BY YEAR-END 2023
    * VYNE THERAPEUTICS INC - EXPECTS TO INITIATE A PHASE 1A
SAD/MAD
CLINICAL TRIAL IN Q1 2024

Source text for Eikon:  ID:nGNX4Q2Gxf 
Further company coverage:  VYNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))